Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
Sponsor: Tongji Hospital
Summary
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of fluzoparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment, and preliminarily evaluate the pharmacoeconomic of fluzoparib in the treatment of ovarian cancer.
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
490
Start Date
2022-01-14
Completion Date
2032-12-31
Last Updated
2022-01-26
Healthy Volunteers
No
Conditions
Interventions
fluzoparib monotherapy or combination therapy
patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
Locations (1)
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China